Targeting Dysregulated Epigenetic Enzymes for Prostate Cancer Treatment
Abstract
New approaches are needed for the treatment of advanced prostate cancer. One understudied area is the alteration to proteins that bind and change the function of DNA termed histone post-translational modifications (PTMs) and the enzymes that cause these changes. These changes have widespread effects on the growth and aggressiveness of cancer cells. To date, this area has not been studied in detail due to limitations in assays and other tools to identify widespread changes in PTMs and the enzymes that "write" or "erase" these modifications. These enzymes are of special interest as a target for cancer therapy. We have developed new technology that screens large numbers of PTMs, and we propose to apply this to prostate cancer to determine which changes underlie the development of advanced prostate cancer. This knowledge will lead to the identification of the enzymes that cause these histone changes, and we propose to extend these findings to test small-molecule effectors of these novel enzymes in prostate cancer as a near-term approach to treating prostate cancer.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Apr 04, 2016
- Source ID
- W81XWH1510628
Entities
People
- David F Jarrard
Organizations
- United States Army
- University of Wisconsin–Madison